SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy

作者：Weitao Shen, Wei Zhang, Weilin Ye, Haihong Wang, Qingxi Zhang, Jie Shen, Qingsha Hong, Xiang Li, Ge Wen, Ting Wei, Jian Zhang · 发表于：Theranostics · 年份：2020 · DOI：10.7150/thno.42478 · 被引用次数：87 · 研究领域：Autophagy in Disease and Therapy、RNA modifications and cancer、Endoplasmic Reticulum Stress and Disease

: Our study provided a novel viewpoint indicating that the REV-ERB agonist SR9009 could be a novel and promising therapeutic strategy in first- or second-line SCLC treatment. The anti-SCLC effect of SR9009 is mediated by REV-ERB dependent suppression of autophagy via direct repression of the autophagy gene Atg5.